Tehran University of Medical Sciences Iranian Journal of Psychiatry 1735-4587 8 4 2013 12 15 201 3 Masoomeh Saeedloo Mental Health Research Center and Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran Seyed Vahid Shariat Mental Health Research Center and Department of Psychiatry, Tehran Institute of Psychiatry-Faculty of Behavioral Sciences and Mental Health, Iran University of Medical Sciences, Tehran, Iran 2015 10 14 Objective: Vitiligo is a rare side effect of carbamazepine whose exact mechanism is unknown. The aim of this report is to describe a single case of vitiligo induced by carbamazepine . Methods: The case was a patient with Bipolar I disorder whose medications were changed from valproate to carbamazepine and who developed vitiligo after a short while. We followed the case for about four years when he was rechallenged with carbamazepine. Results: When depigmentation occurred, we immediately discontinued carbamazepine after which the depigmented areas improved gradually. About three years later, he received carbamazepine again, but depigmentation did not recur. Conclusion: Carbamazepine-induced vitiligo is not an absolute contraindication for the prescription of carbamazepine if other choices fail to respond or are not tolerated. The case has implications for the mechanism of medication induced vitiligo. https://ijps.tums.ac.ir/index.php/ijps/article/view/142 https://ijps.tums.ac.ir/index.php/ijps/article/download/142/138